--- title: "Where Algorithms Meet Apnea: The Hidden Tensions Shaping US Medical Tech in 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/291917805.md" description: "The US medical technology sector is undergoing a profound transformation, moving from cloud-connected devices to AI-driven drug development. As ResMed expands its sleep health empire and Veeva Systems accelerates its AI rollout, these technology-driven incumbents navigate a complex new cycle filled with structural opportunities and unprecedented disruptions." datetime: "2026-07-07T10:38:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/291917805.md) - [en](https://longbridge.com/en/news/291917805.md) - [zh-HK](https://longbridge.com/zh-HK/news/291917805.md) generator: "portal-rs" --- # Where Algorithms Meet Apnea: The Hidden Tensions Shaping US Medical Tech in 2026 When a patient goes to sleep in 2026 wearing a continuous positive airway pressure mask, they are no longer just receiving mechanical therapy — they are continuously feeding data into a cloud-based artificial intelligence system. This seemingly quiet nightly routine illustrates a massive shift: This is a fundamentally different sector sitting in 2026 than it was in 2020. Traditional hardware manufacturers are racing toward the cloud, while software providers are attempting to fundamentally rewire how drugs are developed and commercialized. The core question hanging over the US medical device and services sector today is exactly this: As the historical boundaries of healthcare dissolve, how do these technology-driven incumbents secure their footing in a new cycle, and how vulnerable are they to external disruption? The transformation has been years in the making. ResMed (RMD.US) had decided to move aggressively beyond physical machines to position itself as a global leader in digital health — and then came June 2026. That month, the company closed its acquisition of Noctrix Health to broaden its clinical sleep portfolio, while executives eagerly showcased AI-driven innovations in personalized care at the SLEEP 2026 conference. Yet, the market's response to this evolution remains intricate. In late June, ResMed was unceremoniously removed from several Russell growth indices. But just days later in early July, the narrative flipped when a prominent bank added the company to its APAC Conviction List. The endorsement acted as a powerful signal of confidence in the company's medium-term patient growth, helping shares rally notably in recent sessions. Investors are now heavily focused on the upcoming fiscal fourth-quarter earnings report on August 6. Behind the scenes, however, a broader existential debate lingers: Could the explosive popularity of alternative therapies, specifically GLP-1 weight-loss drugs, permanently erode the baseline demand for sleep apnea treatments? Meanwhile, on the software side of the spectrum, Veeva Systems (VEEV.US) is navigating the complexities of its own expansive ambitions. Long past its days as a simple CRM provider for pharma sales teams, Veeva has embedded itself into the very fabric of drug development. In late June 2026, the company expanded its Quality Cloud with a new Environmental, Health, and Safety (EHS) application and pushed forward with Vault AI. By weaving artificial intelligence directly into pharmacovigilance — the industry's term for the heavily labor-intensive regulatory process of monitoring drug safety — they are promising to automate critical phases of clinical trials. Wall Street is watching this balancing act closely. JPMorgan recently maintained its buy rating on Veeva while slightly adjusting its price expectations downward, reflecting broader macroeconomic calibrations even as the company delivered its fiscal first-quarter 2027 results. With corporate maneuvers — such as President Eleni Nitsa Zuppas recently converting restricted stock units in early July — also in the mix, the picture is one of a mature software giant attempting to maintain disciplined growth while funding a massive technological leap. What all this points to is a medical ecosystem where the flow of data is becoming just as critical as the chemical makeup of a pill. But the structural tensions are far from resolved. What could happen if AI actually allows pharmaceutical companies to develop new drugs at an exponential rate — drugs that could preemptively eliminate the need for an array of traditional medical devices? For this corner of the healthcare market, the real test of resilience is just beginning. *This article does not constitute investment advice.* ### Related Stocks - [RMD.US](https://longbridge.com/en/quote/RMD.US.md) - [VEEV.US](https://longbridge.com/en/quote/VEEV.US.md) ## Related News & Research - [Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor | RMD Stock News](https://longbridge.com/en/news/296141733.md) - [Veeva President, Chief Customer Officer Thomas Schwenger sells USD 8.79 million in common shares](https://longbridge.com/en/news/296144851.md) - [3 arguments for and against AI watermarks](https://longbridge.com/en/news/296205500.md) - [Goldman Sachs Says This 1 Stock Is Set to Be the Biggest AI Productivity Winner](https://longbridge.com/en/news/296259340.md) - [3 AI Stocks Riding The Enterprise Software Push](https://longbridge.com/en/news/296452815.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**